Theseus Pharmaceuticals, Inc. Common Stock
THRX
THRX was delisted on the 13th of February, 2024.
72 hedge funds and large institutions have $351M invested in Theseus Pharmaceuticals, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 22 increasing their positions, 11 reducing their positions, and 2 closing their positions.
1,250% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 2
113% more capital invested
Capital invested by funds: $165M → $351M (+$186M)
100% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 11
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
53% more funds holding
Funds holding: 47 → 72 (+25)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$18.3M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$14.8M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$8.34M |
| 4 |
VA
VR Adviser
New York
|
+$7.56M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$4.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.6M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$884K |
| 3 |
BC
Boxer Capital
San Diego,
California
|
-$638K |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$460K |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$245K |
THRX Hedge Fund Activity: Q1 2023 in Review
72 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Theseus Pharmaceuticals, Inc. Common Stock (THRX) for Q1 2023, worth a combined $351M — up 113% from $165M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new THRX positions and 2 closed out — a net gain of 25 holders — while 22 added to existing stakes and 11 trimmed.
The largest buyer was Fairmount Funds Management, opening a new position worth an estimated $18.3M. The largest seller was Fidelity Investments, cutting an estimated $13.6M.
- 72 institutional investors held Theseus Pharmaceuticals, Inc. Common Stock (THRX) as of Q1 2023, up from 47 in Q4 2022.
- Funds reported $351M of Theseus Pharmaceuticals, Inc. Common Stock stock for Q1 2023, up 113% quarter-over-quarter.
- 27 funds opened new Theseus Pharmaceuticals, Inc. Common Stock positions in Q1 2023 and 2 closed out, a net change of +25 holders.
- The largest Theseus Pharmaceuticals, Inc. Common Stock buyer in Q1 2023 was Fairmount Funds Management, an estimated $18.3M added.
- The largest Theseus Pharmaceuticals, Inc. Common Stock seller in Q1 2023 was Fidelity Investments, an estimated $13.6M sold.
Based on aggregated 13F filings for Q1 2023.